MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603

BACKGROUND: Carboplatin/paclitaxel (CP), with or without sorafenib, result in objective response rates of 18–20 % in unselected chemotherapy-naïve patients. Molecular predictors of survival and response to CP-based chemotherapy in metastatic melanoma (MM) are critical to improving the therapeutic in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Epigenetics
Main Authors: Villaruz, Liza C., Huang, Grace, Romkes, Marjorie, Kirkwood, John M., Buch, Shama C., Nukui, Tomoko, Flaherty, Keith T., Lee, Sandra J., Wilson, Melissa A., Nathanson, Katherine L., Benos, Panayiotis V., Tawbi, Hussein A.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2015
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4457092/
https://ncbi.nlm.nih.gov/pubmed/26052356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13148-015-0092-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados